Ratings Nanobiotix

Equities

NANO

FR0011341205

Real-time Euronext Paris Other stock markets 10:31:21 2024-05-07 am EDT			5-day change	1st Jan Change
6.16 ^EUR	+2.07%		+13.13%	-7.23%

Apr. 25	Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024
Apr. 24	Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
NANOBIOTIX	-7.23%	306M	-
MODERNA, INC.	+20.60%	46.81B	B-
IQVIA HOLDINGS INC.	-0.60%	41.37B	B
LONZA GROUP AG	+46.85%	41.29B	A
CELLTRION, INC.	-6.20%	28.87B	C
ICON PUBLIC LIMITED COMPANY	+10.78%	26.06B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.74%	19.13B	B
MEDPACE HOLDINGS, INC.	+32.03%	12.39B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.18%	12.08B	C+
BIO-TECHNE CORPORATION	-0.14%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes